ROR1 and neoplasm: Another example is given from a preclinical study in which the combination of oxaliplatin and T cells expressing a CAR direct against tyrosine-protein kinase transmembrane receptor (ROR1) improved the anti-tumor activity of the cell therapy increasing T cell homing to the tumor site and their survival (Srivastava et al., 2021).